Lassen Therapeutics to Present at the 5th Annual Idiopathic Pulmonary Fibrosis (IPF) Summit

SAN DIEGO--()--Lassen Therapeutics, a biotech company developing innovative therapeutic antibodies as potential treatments for fibrosis, rare diseases and oncology, today announced that Jamie Swaney, Ph.D., Vice President of Fibrosis & Translational Biology, is presenting at the 5th Annual IPF Summit on Friday, August 27, 2021. The title of his presentation is “Antibody Mediated Blockade of Interleukin-11 Signaling for IPF and Other Fibrosing Lung Diseases”. Dr. Swaney will describe the upregulation of IL-11 in lung fibrosis and the development and characterization of anti-IL-11 receptor antibodies to treat lung fibrosis.

About Lassen Therapeutics

Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than and additive to other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. For more information, please visit www.lassentherapeutics.com

Contacts

Media Contact:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497

Contacts

Media Contact:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497